Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)
研究概览
简要总结
The presence of persistent inadequate or suboptimal virologic response is a strong risk factor for viral resistance and breakthrough and also for disease progression of chronic hepatitis B, and thus, a change in therapy is required. The combination of entecavir (ETV) and adefovir (ADV) is a promising treatment for patients with lamivudine (LAM)-resistance who show suboptimal response to the combination of LAM and ADV.
In this randomized, open labeled trial,the investigators will compare the efficacy of continuation of ADV plus LAM versus switch to ADV plus ETV in adults with LAM-resistant chronic hepatitis B who shows suboptimal response to the combination treatment of ADV and LAM.
详细描述
In this randomized, open label, two-arm, single center phase IV trial, the investigators will assess and compare the efficacy and safety of continuation of ADV plus LAM versus switching to ADV plus ETV up to 52-weeks in Korean adults with chronic hepatitis B who have resistant mutants to LAM and show suboptimal response to combination of ADV plus LAM.
All study subjects who complete the initial treatments of 52-weeks will be thereafter treated with the combination of ADV plus ETV for 52 more weeks.
Study period: Nov 2009 - October 2012 Patient enrollment period: November 2009 - December 2010
Study protocol
- Group A (ADV+LAM group): Adefovir (10 mg/day) + Lamivudine (100 mg/day) for 52 weeks, and thereafter, Adefovir (10 mg/day) + Entecavir (1 mg/day) for 52 more weeks
- Group B (ADV+ETV group): Adefovir (10 mg/day) + Entecavir (1 mg/day) for 104 weeks
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 16 to 75 years of age
- •Compensated liver disease(Child-Pugh class A)
- •HBsAg positive at least 6 months or more
- •HBeAg positive or negative
- •Confirmation of Lamivudine-resistance HBV mutation anytime before the study
- •Patients with suboptimal response (HBV DNA > 2000 IU/mL despite combination of Adefovir [10 mg/day] plus Lamivudine [100 mg/day] for 6 months or more). Serum HBV DNA should be determined by the PCR assay at the local laboratory at screening for this study
- •Patient is ambulatory.
- •Patient is willing and able to comply with the study drug regimen and all other study requirements.
- •The patient is willing and able to provide written informed consent to participate in the study.
排除标准
- •Patient has a history of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies or elevated serum alpha fetoprotein (AFP) levels. In patients with such findings, HCC should be ruled-out prior to randomizing the patient for the present study.
- •Patient previously received oral antiviral agent other than Lamivudine or Adefovir
- •Patient has received interferon or other immunomodulatory treatment for HBV infection within 12 months before screening for this study.
- •Patient has concomitant other chronic viral infection (HCV or HIV)
- •Patient has evidence of renal insufficiency defined as serum creatinine > 1.5 mg/dL
- •Patient has medical condition that requires use of systemic prednisolone or other immunosuppressive agent (including chemotherapeutic agent)
- •Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.
- •Patient is pregnant or breastfeeding or willing to be pregnant
- •Patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease, etc.).
- •A history of treated malignancy (other than hepatocellular carcinoma) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding three years.
- •Clinical signs of decompensated liver disease as indicated by any one of the following:
- •serum bilirubin > 3 mg/dL
- •prothrombin time > 6 seconds prolonged or INR >1.6
- •serum albumin < 2.8 g/dL
- •History of ascites, variceal hemorrhage, or hepatic encephalopathy
- •Child-Pugh score ≥7
研究组 & 干预措施
Adefovir plus Entecavir
Adefovir + Entecavir for 104 weeks
干预措施: Adefovir (Drug)
Adefovir plus Entecavir
Adefovir + Entecavir for 104 weeks
干预措施: Entecavir (Drug)
Adefovir plus Lamivudine
Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
干预措施: Adefovir (Drug)
Adefovir plus Lamivudine
Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
干预措施: Entecavir (Drug)
Adefovir plus Lamivudine
Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
干预措施: Lamivudine (Drug)
结局指标
主要结局
Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)
时间窗: at week 52 from randomization
次要结局
- Reduction in Serum HBV DNA Levels(at week 52 and at week 104 from randomization)
- Genotypic Resistance to ADV or ETV(at week 52 and at week 104 from randomization)
- Normalization of ALT Level(at week 52 and at week 104 from randomization)
- Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)(at week 104 from randomization)
研究者
Young-Suk Lim
Associate Professor
Asan Medical Center